Knowledge HQ

This document describes the AIM platform's ability to enrich and expand antigen-specific CD8+ T cells for viral targets. G-Rex® culture systems were used for the 14-day expansion process.

This review analyzes the landscape of allogeneic NK cell therapies, covering cell sources, engineering, and combination strategies. It highlights the G-Rex® platform as a widely used static bioreactor for the clinical manufacturing of NK cell products, including GDA-201 and cord blood-derived NK cells.

An oncolytic adenovirus expressing human IL-7 (Ad5/3-E2F-d24-hIL7) was developed to activate TILs within the tumor microenvironment. It increased T cell infiltration and caused tumor regression in animal models. G-Rex® culturing plates were used for the rapid expansion of PBMCs in control experiments.

This study establishes a cGMP-compliant manufacturing process for allogeneic CD19-CAR T cells using CD45RA-depleted memory T cells. The process utilizes G-Rex® 6M and G-Rex® 100M-CS devices for efficient cell expansion, ensuring sufficient yield and phenotype preservation for clinical applications.

A Tri-specific Killer Engager (TriKE) targeting TEM8 (cam1615TEM8) was developed to redirect NK cells against both tumor and stromal cells. The molecule enhanced NK cell proliferation and antitumor efficacy in mouse models. Enriched NK cells for in vivo experiments were expanded in G-Rex® 6-well plates.

This study isolates and characterizes neutralizing monoclonal antibodies against Venezuelan equine encephalitis virus (VEEV) from mice and humans. These antibodies target the E2 glycoprotein and protect mice from lethal aerosol challenge. G-Rex® devices were used to expand hybridoma clones in serum-free medium.

The authors developed a feeder-free, xeno-free protocol for NK cell expansion using NK Cloudz microspheres in G-Rex®6M vessels with human platelet lysate. The method achieved ~387-fold expansion in 10 days with high purity and cytotoxicity, offering a scalable alternative to feeder cell-based methods.

This study demonstrates that genome editing with TALEN or CRISPR can restore SAP expression and function in T cells from XLP patients. PBMC stimulation and culture were performed in G-Rex® 24 plates. Edited cells showed physiological SAP levels and restored immune functions, suggesting a viable therapeutic approach.

The authors developed BOXR1030, a GPC3-targeted CAR T cell co-expressing GOT2 to enhance metabolism. T cells were expanded in G-Rex® 10 or 100 units. BOXR1030 demonstrated superior in vivo antitumor activity, reduced exhaustion, and better persistence in solid tumor xenograft models compared to control CARs.

This study optimized the expansion of cytokine-induced killer (CIK) and blinatumomab-expanded T cells (BET) in G-Rex® devices. G-Rex® allowed for expansion to >30 million cells/cm2 in 10-11 days with minimal manipulation, significantly faster than T-flasks, while maintaining cell phenotype and function.

Due to supply chain shortages, the authors validated G-Rex® vessels as an alternative to Wave bioreactors for CAR T expansion. G-Rex® 1L vessels produced 2-4 billion T cells with >90% viability and comparable phenotype/function, using significantly less media and labor than the Wave system.

This paper presents a scalable platform for allogeneic T cell manufacturing using stirred-tank bioreactors (STR) with perfusion. It compares STR performance to G-Rex®, noting that while G-Rex® achieved 28-fold expansion, the perfused STR achieved 167-fold expansion, demonstrating superior scalability.